Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biotechnology company specializing in innovative immunotherapy solutions aimed at rebalancing hyperactive immune responses. The company focuses on treating life-threatening conditions such as Cytokine Release Syndrome (CRS) and sepsis, which can lead to severe organ damage and multiple organ failure. Enlivex's core product, Allocetra™, is designed to modulate the immune system without suppressing it entirely, thereby preventing the harmful effects of immune hyperactivity. The company primarily serves healthcare providers and patients in critical care settings, operating within the biopharmaceutical market. Enlivex's business model revolves around the research, development, and commercialization of its proprietary cell-based therapies. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon regulatory approval.

Keywords: immunotherapy, cytokine storm, CRS, sepsis, organ failure, Allocetra™, immune modulation, biopharmaceutical, cell-based therapy, clinical-stage.